SS-31 (Elamipretide) (SS-31 / Elamipretide (Bendavia))
A mitochondria-targeted tetrapeptide concentrating 1000-5000x in inner mitochondrial membrane. Stabilizes cardiolipin and optimizes electron transport. In clinical trials for Barth syndrome and heart failure.
How it works
Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%.
Key facts
- Molecular weight: 640.8 Da
- Half-life: 4-6 hours
- Bioavailability: High (SubQ)
- Storage: Lyophilized: -20°C. Solution: 2-8°C.
Dosing overview
- Typical dose: 5-40 mg
- Frequency: Daily
- Duration: 4-12 weeks
- Route: Subcutaneous or IV
Reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Possible side effects
- Injection site reactions
- Headache
- Mild GI effects
- Taste disturbance (IV)
Research
- Elamipretide improves mitochondrial function in heart failure (2022): Improved LV function, exercise capacity, and quality of life in HFrEF patients.
- SS-31 reverses age-related mitochondrial dysfunction (2021): Eight weeks restored coupling efficiency and reduced H2O2 emission by 50% in aged skeletal muscle.
Compare SS-31 (Elamipretide)
Research and educational reference only. Not medical advice.